QuidelOrtho Corp is a prominent player in the field of medical diagnostics, specializing in the development and manufacture of diagnostic testing solutions. The company focuses on producing innovative products that aid in the rapid detection of infectious diseases and other critical health conditions, utilizing advanced technologies such as molecular diagnostics and immunoassay platforms. QuidelOrtho's portfolio includes a range of tests designed for use in various healthcare settings, including hospitals, laboratories, and physician offices, facilitating timely and accurate diagnoses that enhance patient care. Through its commitment to innovation and quality, the company strives to improve the health outcomes of individuals around the globe.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
QuidelOrtho secures FDA approval for QuickVue COVID-19 test, catering to home and medical settings. Despite Savanna RVP4+ assay withdrawal, company promises a new multiplex assay for 2024/2025 respiratory season.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of March 4-8.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Feb. 12-16, 2024.
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.11% to 38,313.27 while the NASDAQ rose 0.70% to 15,765.18. The S&P 500 also rose, gaining, 0.49% to 4,977.43.
The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation report in January, as investors refocused on corporate earnings.
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.
